Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EU101 in advanced solid tumors
NCT04903873Phase 2Recruiting
- Sponsor
- Eutilex Co., Ltd.
- Start
- May 2021
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of EU101 in solid tumor, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), sponsored by Eutilex Co., Ltd.. Started May 2021; status: recruiting.
02
Drugs
EU101
03
Conditions
solid tumorcolorectal cancer (CRC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04903873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04903873.